New drug Rylaze recorded sales of $101.7 million in the quarter, up 39% year over year. Jazz stated that demand remained strong during the quarter. Rylaze is only approved in the United States for treating acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients. A regulatory application seeking approval for this drug seeking approval for ALL and LBL indications is currently under review in Europe, with a decision expected later this year.